TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) (the “Company”) announced today its financial results for the three months ended March 31, 2025 (“Q1 2025”). Q1 2025 Highlights1 Strong top-line income and distributable income: Net investment income of $28.6 million compared to $24.6 million in Q1 2024.Net income and comprehensive income of $14.8 million (Q1 2024 – $14.4 million) or basic earnings per share of $0.18 (Q1 2024 – $0.17).Distributable income of $15.4 million ($0.19 per s ...

Core Viewpoint - Ero Copper Corp. reported strong operational and financial results for Q1 2025, driven by increased copper production and higher metals prices, with a focus on achieving record copper production in 2025 [1][4][7]. Financial Highlights - Revenues for Q1 2025 were $125.1 million, up from $122.5 million in Q4 2024 and $105.8 million in Q1 2024 [13]. - Net income attributable to owners of the Company was $80.2 million ($0.77 per diluted share), a significant recovery from a net loss of $48.9 million in Q4 2024 [13][14]. - Adjusted EBITDA for the quarter was $63.2 million, compared to $59.1 million in Q4 2024 and $43.3 million in Q1 2024 [13][34]. Operational Highlights - Consolidated copper production reached 12,424 tonnes, with the Tucumã Operation contributing 5,067 tonnes and Caraíba Operations producing 7,357 tonnes [5][11]. - Gold production totaled 6,638 ounces, with average C1 cash costs of $1,100 per ounce and All-in Sustaining Costs (AISC) of $2,228 per ounce [5][12]. - The company achieved a 32% quarter-on-quarter increase in ore tonnes processed at the Tucumã Operation, with more than half of the production occurring in March 2025 [11][15]. Production and Cost Guidance - Ero Copper expects full-year copper production for 2025 to range between 75,000 and 85,000 tonnes, with sequential increases anticipated throughout the year [15][17]. - The company reaffirmed its gold production guidance of 50,000 to 60,000 ounces for the Xavantina Operations, supported by higher processed tonnage and improved gold grades [16][17]. Capital Expenditure Guidance - Capital expenditure guidance for 2025 remains unchanged at $230 to $270 million, excluding capitalized ramp-up costs prior to the declaration of commercial production at the Tucumã Operation [20][21]. Liquidity Position - At the end of Q1 2025, available liquidity was $115.6 million, including $80.6 million in cash and cash equivalents and $35 million of undrawn availability under the senior secured revolving credit facility [5][43].

Core Insights - Kneat.com, inc. has announced an expansion of its executive leadership team to enhance innovation and product development as it scales to meet global customer demand [1][2] Leadership Changes - Kevin Fitzgerald, co-founder and current Chief Product Officer, will transition to the newly created role of Chief Innovation Officer in early June 2025, allowing him to focus on the strategic vision and innovation of Kneat's products [3] - Donal O'Sullivan will join Kneat as Chief Product Officer, bringing over 25 years of experience in software development leadership roles, previously serving as CPO at My Compliance Office [4][5] Strategic Focus - The restructuring aims to optimize product operational excellence and strategic planning, providing necessary leadership and governance as the company grows [2][6] - The leadership changes are expected to better position the company to capture growth opportunities in the market [6] Product Overview - Kneat Solutions offers a digital validation platform, Kneat Gx, which is designed for highly regulated industries, ensuring compliance and efficiency [7] - The platform is fully certified and compliant with ISO standards and regulatory requirements, demonstrating significant improvements in documentation cycle times and speed to market [7]

Group 1 - Kane Biotech Inc. has completed a non-brokered private placement offering, issuing 12,000,000 common shares at a price of $0.10 per share, resulting in gross proceeds of $1,200,000 [2] - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2] - The company has also secured an unsecured loan of $1,000,000 from an insider, which is interest-free and repayable on demand [3] Group 2 - The transactions are classified as "related party transactions" under Multilateral Instrument 61-101, with the company exempt from formal valuation and minority approval requirements [4] - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which contribute to antibiotic resistance and complicate wound healing [6]

Core Insights - AGF Management Limited reported total assets under management (AUM) and fee-earning assets of $51.3 billion as of April 30, 2025 [1][6]. AUM Summary - Total AUM decreased by 1.6% from $50.0 billion in March 2025 to $49.2 billion in April 2025, but increased by 7.7% compared to $45.7 billion in April 2024 [2]. - Total fee-earning assets remained stable at $2.1 billion, resulting in total AUM and fee-earning assets of $51.3 billion, down 1.5% from $52.1 billion in March 2025 and up 7.3% from $47.8 billion in April 2024 [2]. Mutual Fund AUM by Category - Domestic Equity Funds AUM was $4.3 billion in April 2025, slightly down from $4.4 billion in March 2025 and up from $4.1 billion in April 2024 [3]. - U.S. and International Equity Funds AUM was $18.0 billion, down from $18.1 billion in March 2025 and up from $15.4 billion in April 2024 [3]. - Domestic Fixed Income Funds AUM remained stable at $2.0 billion, up from $1.6 billion in April 2024 [3]. Company Overview - AGF Management Limited, founded in 1957, is an independent and globally diverse asset management firm with operations in North America and Europe [4][6]. - The firm focuses on responsible and sustainable corporate practices, serving a wide range of clients including financial advisors, high-net-worth individuals, and institutional investors [5][6].

Core Insights - BellRing Brands, Inc. reported strong financial results for the second fiscal quarter ended March 31, 2025, with net sales reaching $588.0 million, an increase of 18.9% year-over-year, driven by volume growth and price/mix improvements [4][10][15]. Financial Performance - Adjusted EBITDA for the second quarter was $118.6 million, reflecting a 14.4% increase compared to the prior year [14]. - Gross profit was $189.8 million, or 32.3% of net sales, up 15.5% from $164.3 million, or 33.2% of net sales, in the previous year [7][34]. - Selling, general and administrative (SG&A) expenses increased to $90.5 million, representing 15.4% of net sales, compared to $69.1 million, or 14.0% of net sales, in the prior year [9][18]. Product Performance - Premier Protein net sales increased by 22.0%, driven by a 15.3% volume growth and a 6.7% increase in price/mix [5][15]. - Dymatize net sales grew by 3.0%, with a significant 20.4% increase in volume, although this was partially offset by a 17.3% decrease in price/mix [6][15]. Market Trends - The consumption of Premier Protein ready-to-drink shakes and powder products saw increases of 24.9% and 21.7%, respectively, indicating strong market demand [3]. - The company continues to expect net sales growth of 13% to 17% for fiscal year 2025, despite macroeconomic uncertainties [3][24]. Share Repurchase Activity - During the second quarter, BellRing repurchased 2.4 million shares for $171.7 million at an average price of $71.68 per share, with $280.0 million remaining under its share repurchase authorization as of March 31, 2025 [23]. Outlook - The company has affirmed its fiscal year 2025 outlook, expecting net sales to range between $2.26 billion and $2.34 billion, and Adjusted EBITDA to range between $470 million and $500 million [24].

Group 1 - Sanuwave Health, Inc. will host a live conference call on May 9, 2025, at 8:30 AM (ET) to present its Q1 2025 financial results [1][2] - The company specializes in next-generation FDA-approved wound care products and is focused on the research, development, and commercialization of non-invasive medical systems [2][3] - Sanuwave's product portfolio includes regenerative medicine products aimed at restoring normal healing processes in various medical conditions [3] Group 2 - The conference call will provide access via toll-free and international numbers, with a replay available until May 30, 2025 [1][2] - Materials related to the conference call will be accessible on the company's investor website [2] - Sanuwave applies patented energy transfer technologies in multiple fields, including wound healing and orthopedic conditions [3]

(All dollar amounts are expressed in Canadian dollars, unless otherwise noted.) TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Kinross Gold Corporation (“Kinross” or the “Company”) (TSX: K, NYSE: KGC) announced today that it has acquired an aggregate of 7,574,237 units (each, a “Unit”) of Eminent Gold Corp. (“Eminent”) at a price of $0.40 per Unit and an aggregate purchase price of $3,029,694.80 (the “Acquisition”), pursuant to the closing of a private placement by Eminent of 10,711,900 Units. Each Unit consist ...

Increased Net Sales 3.1 percent to $364.3 Million Reported Net Income per Diluted Share of $0.33 Achieved Adjusted Net Income per Diluted Share of $0.34 Raises Annual Guidance for Fiscal 2025 Net Sales Reaffirms Annual Guidance for Fiscal 2025 Adjusted EBITDA ATLANTA, May 05, 2025 (GLOBE NEWSWIRE) -- Mueller Water Products, Inc. (NYSE: MWA), a leading manufacturer and marketer of products and solutions used in the transmission, distribution and measurement of water in North America, announced financial resu ...

PHOENIX, May 05, 2025 (GLOBE NEWSWIRE) -- Fold Holdings, Inc. (NASDAQ: FLD) (“Fold” or the “Company”), the first publicly traded bitcoin financial services company, announces the appointment of Matthew McManus as Chief Operating Officer, effective April 21, 2025. In his new role, Mr. McManus will spearhead Fold’s operational strategy, partnering closely with senior leadership to accelerate growth, optimize performance, and solidify the Company’s leadership position at the forefront of the bitcoin financial ...